Robert Ang - Jan 29, 2024 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Katie Kazem, Attorney-in-Fact
Stock symbol
VOR
Transactions as of
Jan 29, 2024
Transactions value $
$0
Form type
4
Date filed
1/31/2024, 07:35 PM
Previous filing
Nov 8, 2023
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VOR Common Stock Award $0 +150K +22.03% $0.00 831K Jan 29, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VOR Employee Stock Option (right to buy) Award $0 +470K $0.00 470K Jan 29, 2024 Common Stock 470K $2.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest over four years in equal quarterly installments beginning on February 1, 2024, subject to the Reporting Person's continued service as of each such date.
F2 The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on February 1, 2024, in each case subject to the Reporting Person's continued service as of each such date.